Anti-cancer activity of trans-chalcone in osteosarcoma: Involvement of Sp1 and p53

Molecular Carcinogenesis

Volumn 55, Issue 10, 2016, Pages 1438-1448

  Silva, Gabriel ^a,b   Marins, Mozart ^b   Fachin, Ana Lúcia ^b   Lee, Seong Ho ^c   Baek, Seung Joon ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

chalcone; osteosarcoma; p53; Sp1; transcriptional regulation

Indexed keywords

ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; PROTEIN P53; TRANS CHALCONE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; DOSE TIME EFFECT RELATION; HCT116 CELL LINE; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; U2OS CELL LINE;

EID: 84986903582     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22386     Document Type: Article

References (34)

1. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer 2014; 14:722–735.
2. Jandial DD, Blair CA, Zhang S, Krill LS, Zhang Y-B, Zi X. Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr Cancer Drug Tar 2014; 14:181–200.
3. Yadav VR, Prasad S, Sung B, Aggarwal BB. The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int Immunopharmacol 2011; 11:295–309.
4. Sisodia BS, Negi AS, Darokar MP, Dwivedi UN, Khanuja SPS. Antiplasmodial activity of steroidal chalcones: Evaluation of their effect on hemozoin synthesis and the new permeation pathway of plasmodium falciparum-infected erythrocyte membrane. Chem Biol Drug Design 2012; 79:610–615.
5. Bitencourt TA, Komoto TT, Massaroto BG, et al. Trans-chalcone and quercetin down-regulate fatty acid synthase gene expression and reduce ergosterol content in the human pathogenic dermatophyte Trichophyton rubrum. BMC Complement Altern Med. 2013; 13:229.
6. Orlikova B, Tasdemir D, Golais F, Dicato M, Diederich M. Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr 2011; 6:125–147.
7. Silva G, Fachin AL, Beleboni RO, Franca SC, Marins M. In vitro action of flavonoids in the canine malignant histiocytic cell line DH82. Molecules (Basel, Switzerland) 2013; 18:15448–15463.
8. Safe S, Imanirad P, Sreevalsan S, Nair V, Jutooru I. Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target. Expert Opin Ther Targets 2014; 18:759–769.
9. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41:2438–2448.
10. Williams A, Isaacs R, Stowell K. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions. BMC Mol Biol 2007; 8:36.
11. Li H, Zhang Y, Strose A, Tedesco D, Gurova K, Selivanova G. Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death Differ 2014; 21:1493–1502.
12. Marcel V, Catez F, Diaz JJ. P53, a translational regulator: contribution to its tumour-suppressor activity. Oncogene 2015.
13. Essmann F, Schulze-Osthoff K. Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol 2012; 165:328–344.
14. Wilson H, Chadalapaka G, Jutooru I, et al. Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (Sp) transcription factors, and Sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells. J Vet Intern Med 2012; 26:977–986.
15. Yu K, Shi Y-F, Yang K-Y, et al. Decreased topoisomerase IIα expression and altered histone and regulatory factors of topoisomerase IIα promoter in patients with chronic benzene poisoning. Toxicol Lett 2011; 203:111–117.
16. Kambe A, Iguchi G, Moon Y, Kamitani H, Watanabe T, Eling TE. Regulation of EP4 expression via the Sp-1 transcription factor: Inhibition of expression by anti-cancer agents. Biochim Biophys Acta - Mol Cell Res 2008; 1783:1211–1219.
17. Zhong Y, Krisanapun C, Lee S-H, et al. Molecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53. Eur J Cancer. 2010; 46:3365–3374.
18. Baek SJ, Horowitz JM, Eling TE. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter: Basal transcription is mediated by Sp1 and Sp3. J Biol Chem. 2001; 276:33384–33392.
19. Cabrera M, Simoens M, Falchi G, et al. Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure-activity relationships. Bioorg Med Chem 2007; 15:3356–3367.
20. Li L, Davie JR. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 2010; 192:275–283.
21. Mertens-Talcott SU, Noratto GD, Li X, Angel-Morales G, Bertoldi MC, Safe S. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZB TB10. Mol Carcinog 2013; 52:591–602.
22. Zhao Y, Zhang W, Guo Z, et al. Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts. Oncol Rep. 2013; 30:1782–1792.
23. Noratto GD, Jutooru I, Safe S, Angel-Morales G, Mertens-Talcott SU. The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis. Mol Nutr Food Res 2013; 57:1638–1648.
24. Zhou N, Yan Y, Li W, et al. Genistein inhibition of topoisomerase IIalpha expression participated by Sp1 and Sp3 in HeLa cell. Int J Mol Sci 2009; 10:3255–3268.
25. Guan H, Cai J, Zhang N, et al. Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer 2012; 130:593–601.
26. Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 2010; 396:85–89.
27. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. Tumour suppression by p53: The importance of apoptosis and cellular senescence. J Pathol 2009; 219:3–15.
28. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008; 20:90–96.
29. Ding WX, Ni HM, Chen X, Yu J, Zhang L, Yin XM. A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol Cancer Ther 2007; 6:1062–1069.
30. Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003; 63:7338–7344.
31. Tampio M, Loikkanen J, Myllynen P, Mertanen A, Vahakangas KH. Benzo(a) pyrene increases phosphorylation of p53 at serine 392 in relation to p53 induction and cell death in MCF-7 cells. Toxicol Lett 2008; 178:152–159.
32. Cox ML, Meek DW. Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. Cell Signal 2010; 22:564–571.
33. Gu B, Zhu WG. Surf the post-translational modification network of p53 regulation. Int J Biol Sci 2012; 8:672–684.
34. Lambert JD, Lee MJ, Lu H, et al. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 2003; 133:4172–4177.